Publications

McAlister SM, Dierig A, van den Biggelaar AH, Thornton R, Cooper MN, McIntyre P, Richmond PC, Wood N. Immunogenicity and safety of a 2 + 1 DTPa priming schedule in Australian infants and the impact of maternally derived antibodies on pertussis antibody responses up to 4 years of age. Journal of the Pediatric Infectious Diseases Society 2025;14:piaf067. doi: 10.1093/jpids/piaf067. [Abstract]

Jayasinghe S, Williams PC, Macartney KK, Crawford NW, Blyth CC. Assessing the impact of pneumococcal conjugate vaccine immunization schedule change from 3+0 to 2+1 in Australian children: a retrospective observational study. Clinical Infectious Diseases 2025;80:207-214. doi: 10.1093/cid/ciae377. [Full text]

Hull B, Hendry A, Dey A, Brotherton J, Macartney K, Beard F. Annual Immunisation Coverage Report 2022. Communicable Diseases Intelligence (2018) 2025;49. doi: 10.33321/cdi.2025.49.023. [Full text]

Patel C, Wang X, Giles M, Burns P, Nguyen T, Macartney K, Williams PC. The role of serological testing for vaccination with a focus on immunocompromised patients: a synthesis of current evidence. Vaccine 2025;63:127659. doi: 10.1016/j.vaccine.2025.127659. [Full text]

Bolsewicz KT, Steffens MS, Dalton L, Kaufman J, Christou-Ergos M, Sabahelzain M, Beard F, Danchin M, Leask J. Getting more kids vaccinated on time: strategies and broader policy considerations to address caregiver-identified barriers to childhood immunisation in Australia. Australian and New Zealand Journal of Public Health 2025;49:100274. doi: 10.1016/j.anzjph.2025.100274 . [Full text]

Croker Z, McLure A, Pillsbury A, Deng L, Quinn H. Reduction in self-reported adverse events in Australian adults after change to national immunisation schedule from polysaccharide to conjugate pneumococcal vaccine, 2016-2022. Vaccine 2025;61:127432. doi: 10.1016/j.vaccine.2025.127432. [Full text]

Koirala AH, Prasad SA, Britton PN, Wood NO, Richmond PC, McMullan BN, Crawford NW, Marshall HS, Francis LU, Wills ME, Leighton EM, Macartney K, Bolsewicz KR. Understanding motivation and experience in participating in a paediatric SARS-CoV-2 serosurvey, in Australia. Vaccine: X 2025;27:100716.
doi:10.1016/j.jvacx.2025.100716 (Epub). [Full text]

Croker Z, McLure A, Pillsbury A, Deng L, Quinn H. Reduction in self-reported adverse events in Australian adults after change to national immunisation schedule from polysaccharide to conjugate pneumococcal vaccine, 2016-2022. Vaccine 2025;61:127432. doi: 10.1016/j.vaccine.2025.127432 (Epub). [Full text]

White E, Baik MK, Zahir SF, Blyth CC, Carr J, Crawford NW, Francis JR, Marshall HS, Carey E, Macartney K, McMullan B, Wood N, Britton PN, Clark JE; PAEDS network. Management and outcomes of children hospitalised with COVID-19 including incidental and nosocomial infections in Australia 2020-2023: a national surveillance study. Journal of Clinical Virology 2025;179:105824. doi: 10.1016/j.jcv.2025.105824. [Abstract]

Proboste T, Lau CL, Clark N, Jagals P, Sly PD, Lambert SB, Devine G, Zuccon G, Soares Magalhães RJ. The epidemiology of hospitalisations from four key environmentally sensitive zoonotic diseases in Queensland, 2012-2019. Tropical Medicine & International Health 2025;30:838-847. doi: 10.1111/tmi.14139. [Full text]